4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($0.77), $0.01 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $848.33 thousand.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.